74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Xencor Inc
Closed
SectorHealthcare
10.81 -0.55
Overview
Share price change
24h
Min
10.32
Max
10.91
Income | -5.7M -54M |
|---|---|
Sales | 59M 70M |
EPS | -0.62 |
Profit margin | -77.303 |
Employees | 250 |
EBITDA | 27M -16M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +172.14% upside |
Next Earnings | 7 May 2025 |
|---|
Market Cap | -370M 747M |
|---|---|
Previous open | 11.36 |
Previous close | 10.81 |
Technical Score
By Trading Central
Confidence
Very Strong Bullish Evidence
Xencor Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Xencor Inc Forecast
Price Target
By TipRanks
172.14% upside
12 Months Forecast
Average 29.5 USD 172.14%
High 38 USD
Low 22 USD
Based on 10 Wall Street analysts offering 12 month price targets forXencor Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Xencor Inc
Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.
